会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 76. 发明授权
    • Crystal resonator
    • 水晶谐振器
    • US07902721B2
    • 2011-03-08
    • US11991353
    • 2006-09-14
    • Hiroshi Maeda
    • Hiroshi Maeda
    • H01L41/047H01L41/09
    • H03H9/132H03H9/19
    • A crystal resonator comprises an AT-cut crystal vibrating element that is driven by a thickness-shear mode and is in the shape of a rectangular plate. A pair of excitation electrodes is formed, facing front and rear surfaces of the crystal vibrating element. Each of the excitation electrodes is formed in the shape of a quadrangle as viewed from the top, and mass adjustment portions are formed at least two opposite sides of each of the excitation electrodes formed on the front and rear surfaces.
    • 晶体谐振器包括由厚度剪切模式驱动并且呈矩形板形状的AT切割晶体振动元件。 形成一对激励电极,其面对晶体振动元件的前表面和后表面。 每个激励电极从顶部形成为四边形,并且质量调节部分形成在形成在前表面和后表面上的每个激励电极的至少两个相对侧。
    • 78. 发明申请
    • NOVEL CHONDROITIN SULFATE HAVING DECREASED MOLECULAR WEIGHT AND USE THEREOF
    • 具有降解分子量的新型磺酸钠及其用途
    • US20100286085A1
    • 2010-11-11
    • US12680995
    • 2008-10-01
    • Kazuhiro KojimaYukio GotoHiroshi Maeda
    • Kazuhiro KojimaYukio GotoHiroshi Maeda
    • A61K31/715C08B37/08A61P7/02
    • A61M1/287A61K31/726A61K31/737C08B37/0069C08J3/28C08J2305/08C08K3/02C08K3/08C08K5/09C08L5/08
    • An object of the present invention is to provide a chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65 o to 100% (molar ratio) of the total. -[4GlcAβ1-3GalNAc(6S)β1]- (wherein GlcA represents a D-glucuronic acid residue; GalNAc represents an N-acetyl-D-galactosamine residue; β1-3 represents a β1-3 glycosidic linkage; β1-4 represents a β1-4 glycosidic linkage; and (6S) indicates that position 6 of the monosaccharide residue is sulfated)
    • 本发明的目的是提供一种具有降低的分子量的硫酸软骨素,其具有作为腹膜病的抑制剂的作用,其可以长期使用含有葡萄糖或其多糖的腹膜透析液作为渗透剂,利用为 腹膜透析液中的渗透剂等。 本发明的分子量降低的硫酸软骨素作为实现目的的手段,其特征在于重均分子量为1000〜20000,含有下列结构式所示的构成的二糖单元,其量为 65〜100%(摩尔比)。 - [4GlcA&bgr; 1-3GalNAc(6S)&bgr; 1] - (其中GlcA表示D-葡萄糖醛酸残基; GalNAc表示N-乙酰基-D-半乳糖胺残基;< bgr; 1-3代表& 糖苷键; 1-4表示1-4糖苷键;(6S)表示单糖残基的6位被硫酸化)